Azathioprine oral dispersible - Mitsubishi Tanabe

Drug Profile

Azathioprine oral dispersible - Mitsubishi Tanabe

Alternative Names: Azanin; JP azathioprine tablets

Latest Information Update: 02 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Antirheumatics; Purines; Small molecules; Thionucleosides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Connective tissue disorders; Crohn's disease; Dermatomyositis; Polymyositis; Scleroderma; Systemic lupus erythematosus; Transplant rejection; Ulcerative colitis; Vasculitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 02 Jun 2011 Registered for Connective tissue disorders in Japan (PO)
  • 02 Jun 2011 Registered for Dermatomyositis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top